{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:47:26Z","timestamp":1792396046433,"version":"4.4.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the bayesian approach will only continue to increase. Innovations possible when using the bayesian approach improve the efficiency of drug development and the accuracy of clinical trials, especially in the context of substantial data missingness.<\/jats:p><\/jats:sec>Objective<\/jats:title>To explain the foundations, interpretations, and scientific justification of the bayesian approach in the setting of lecanemab trial 201, a bayesian-designed phase 2 dose-finding trial; to demonstrate the efficiency of using a bayesian design; and to show how it accommodates innovations in the prospective design and also treatment-dependent types of missing data.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This study was a bayesian analysis of a clinical trial comparing the efficacy of 5 lecanemab 201 dosages for treatment of early Alzheimer disease. The goal of the lecanemab 201 trial was to identify the effective dose 90 (ED90), the dose achieving at least 90% of the maximum effectiveness of doses considered in the trial. This study assessed the bayesian adaptive randomization used, in which patients were preferentially assigned to doses that would give more information about the ED90 and its efficacy.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients in the lecanemab 201 trial were adaptively randomized to 1 of 5 dose regimens or placebo.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point of lecanemab 201 was the Alzheimer Disease Composite Clinical Score (ADCOMS) at 12 months with continued treatment and follow-up out to 18 months.<\/jats:p><\/jats:sec>Results<\/jats:title>A total 854 patients were included in trial treatment: 238 were in the placebo group (median age, 72 years [range, 50-89 years]; 137 female [58%]) and 587 were assigned to a lecanemab 201 treatment group (median age, 72 years [range, 50-90 years]; 272 female [46%]). The bayesian approach improved the efficiency of a clinical trial by prospectively adapting to the trial\u2019s interim results. By the trial\u2019s end more patients had been assigned to the better-performing doses: 253 (30%) and 161 (19%) patients to 10 mg\/kg monthly and 10 mg\/kg biweekly vs 51 (6%), 52 (6%), and 92 (11%) patients to 5 mg\/kg monthly, 2.5 mg\/kg biweekly, and 5 mg\/kg biweekly, respectively. The trial identified 10 mg\/kg biweekly as the ED90. The change in ADCOMS of the ED90 vs placebo was \u22120.037 at 12 months and \u22120.047 at 18 months. The bayesian posterior probability that the ED90 was superior to placebo was 97.5% at 12 months and 97.7% at 18 months. The respective probabilities of super-superiority were 63.8% and 76.0%. The primary analysis of the randomized bayesian lecanemab 201 trial found in the context of missing data that the most effective dose of lecanemab nearly doubles its estimated efficacy at 18 months of follow-up in comparison with restricting analysis to patients who completed the full 18 months of the trial.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Innovations associated with the bayesian approach can improve the efficiency of drug development and the accuracy of clinical trials, even in the context of substantial data missingness.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01767311<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.7230","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:01:36Z","timestamp":1681225296000},"page":"e237230","source":"Crossref","is-referenced-by-count":28,"title":["Lecanemab for Patients With Early Alzheimer Disease"],"prefix":"10.1001","volume":"6","author":[{"given":"Donald A.","family":"Berry","sequence":"first","affiliation":[{"name":"Berry Consultants, LLC, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kanekiyo","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Li","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad J.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Eisai Inc, Woodcliff Lake, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Berry","sequence":"additional","affiliation":[{"name":"Berry Consultants, LLC, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"1","key":"zoi230237r1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval.","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"zoi230237r2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.2018.13027","article-title":"Promising results in 18-month analysis of Alzheimer drug candidate.","volume":"320","author":"Abbasi","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"zoi230237r3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2020.4478","article-title":"Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease.","volume":"78","author":"Musiek","year":"2021","journal-title":"JAMA Neurol"},{"issue":"11","key":"zoi230237r4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jamaneurol.2021.3404","article-title":"What the aducanumab approval reveals about Alzheimer disease research.","volume":"78","author":"Manly","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi230237r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer\u2019s disease.","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi230237r6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u00df protofibril antibody.","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"zoi230237r10","doi-asserted-by":"publisher","DOI":"10.34133\/2019\/5341375","article-title":"Promising results from Alzheimer's disease passive immunotherapy support the development of a preventive vaccine.","author":"Marciani","year":"2019","journal-title":"Research"},{"issue":"1","key":"zoi230237r11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials.","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"zoi230237r14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.molonc.2015.02.011","article-title":"The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research.","volume":"9","author":"Berry","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"zoi230237r15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cpt.285","article-title":"Emerging innovations in clinical trial design.","volume":"99","author":"Berry","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"zoi230237r16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jama.2009.2029","article-title":"Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.","volume":"303","author":"Wilber","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"zoi230237r17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/dom.12305","article-title":"Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).","volume":"16","author":"Skrivanek","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"zoi230237r19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/WAD.0000000000000093","article-title":"Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.","volume":"29","author":"Lenz","year":"2015","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"zoi230237r22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1586\/14737175.2015.995168","article-title":"Charting a path toward combination therapy for Alzheimer\u2019s disease.","volume":"15","author":"Stephenson","year":"2015","journal-title":"Expert Rev Neurother"},{"issue":"22","key":"zoi230237r23","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/jama.2012.4174","article-title":"Adaptive clinical trials: a partial remedy for the therapeutic misconception?","volume":"307","author":"Meurer","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"zoi230237r25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials.","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"356","key":"zoi230237r26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","article-title":"Science and statistics.","volume":"71","author":"Box","year":"1976","journal-title":"J Am Stat Assoc"},{"key":"zoi230237r24","volume-title":"The Prevention and Treatment of Missing Data in Clinical Trials","author":"National Research Council Panel on Handling Missing Data in Clinical Trials","year":"2010"},{"key":"zoi230237r7","unstructured":"Herper? M. Biogen and Eisai Say Alzheimer's Drug a Success, Reversing Earlier Result. Forbes Healthcare. July 5, 2018. Accessed April 10, 2022. https:\/\/www.forbes.com\/sites\/matthewherper\/2018\/07\/05\/biogen-and-eisai-say-alzheimers-drug-a-success-reversing-earlier-result\/?sh=54a140b428b4"},{"key":"zoi230237r8","unstructured":"Lowe? D. Biogen and Eisai Tease an Alzheimer's Result. Science blog. July 6, 2018. Accessed April 10, 2022. https:\/\/www.science.org\/content\/blog-post\/biogen-and-eisai-tease-alzheimer-s-result"},{"key":"zoi230237r9","unstructured":"Topline results: 18 months of BAN2401 might work, Alzforum. July 7, 2018. Accessed April 10, 2022. https:\/\/www.alzforum.org\/news\/research-news\/topline-results-18-months-ban2401-might-work"},{"key":"zoi230237r12","unstructured":"Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. Docket Number: FDA-2018-D-3124. US Food and Drug Administration. November 2019. Accessed April 10, 2022. https:\/\/www.fda.gov\/media\/78495\/download"},{"key":"zoi230237r13","unstructured":"Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry. Docket Number: FDA-2019-D-3679. US Food and Drug Administration. December 2020. Accessed April 10, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products"},{"key":"zoi230237r18","unstructured":"US Food and Drug Administration. Critical Path Initiative. FDA website. Last updated April 23, 2018. Accessed April 10, 2022. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/critical-path-initiative"},{"key":"zoi230237r20","unstructured":"Can Adaptive Trials Ride to the Rescue? Alzforum. March 16, 2011. Accessed April 10, 2022. https:\/\/www.alzforum.org\/news\/research-news\/can-adaptive-trials-ride-rescue"},{"key":"zoi230237r21","unstructured":"CTAD: Adaptive Antibody Trial to Try Bayesian Statistics. Alzforum. November 13, 2012. Accessed April 10, 2022. https:\/\/www.alzforum.org\/news\/conference-coverage\/ctad-adaptive-antibody-trial-try-bayesian-statistics"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803673\/berry_2023_oi_230237_1680623485.62644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:01:42Z","timestamp":1681225302000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803673"}},"subtitle":["Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7230","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}